[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-myelomonocytic-leukemia:idh2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Myelomonocytic Leukemia","IDH2 Gene",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[12],"Phase 2","RECRUITING","2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03383575","Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome",[12],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:26.928444Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT03683433","Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",[12],"2026-08-26T02:15:43.339060Z","2026-04-29T02:57:57.075222Z"]